Sutro Biopharma, Inc. (STRO)
After hours:
| Previous close | 4.3500 |
| Open | 4.3400 |
| Bid | 4.1300 x 200 |
| Ask | 4.1600 x 100 |
| Day's range | 4.0900 - 4.3700 |
| 52-week range | 2.0100 - 6.1300 |
| Volume | |
| Avg. volume | 997,554 |
| Market cap | 339.324M |
| Beta (5Y monthly) | 1.09 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.7800 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.80 |
ZacksAnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?
AnaptysBio (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
GlobeNewswireSutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1 have been enrolled and are in follow up – SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today
Simply Wall St.Sutro Biopharma, Inc. (NASDAQ:STRO) Analysts Just Cut Their EPS Forecasts Substantially
The analysts covering Sutro Biopharma, Inc. ( NASDAQ:STRO ) delivered a dose of negativity to shareholders today, by...
